Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MNRR1 is a driver of ovarian cancer progression

ABSTRACT: MNRR1 is a driver of ovarian cancer progression

PROVIDER: PRJNA903221 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR22342711_1.fastq.gz	Fastqsanger.gz
	SRR22342711_2.fastq.gz	Fastqsanger.gz
	SRR22342712_1.fastq.gz	Fastqsanger.gz
	SRR22342712_2.fastq.gz	Fastqsanger.gz
	SRR22342713_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Acetate is a driver of quiescence in ovarian cancer

Project description:Acetate is a driver of quiescence in ovarian cancer

| PRJNA1129463 | ENA

MNRR1 is a driver of ovarian cancer progression

Project description:This study was conducted to investigate the role of MNRR1 in regulating the extracellular matrix and focal adhesion modulating ovarian cancer metastasis

2023-01-15 | GSE218364 | GEO

NSD2 is a conserved driver of metastatic prostate cancer progression.

Project description:NSD2 is a conserved driver of metastatic prostate cancer progression.

| PRJNA436465 | ENA

COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer.

2014-01-01 | GSE44104 | GEO

COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer.

Project description:Biomarkers that predict disease progression might assist the development of better therapeutic strategies for aggressive cancers, such as ovarian cancer. Here, we investigated the role of collagen type XI alpha 1 (COL11A1) in cell invasiveness and tumor formation and the prognostic impact of COL11A1 expression in ovarian cancer. Microarray analysis suggested that COL11A1 is a disease progression-associated gene that is linked to ovarian cancer recurrence and poor survival. Whole tumor gene expression profiling was conducted on tissue samples from 60 ovarian cancer patients, and characteristics and clinico-pathological features of the patients are provided. We used several steps to analyze the expression profiles of the samples to identify the genes whose expression values correlate with survival, recurrence and advanced disease stage. First, using hazard ratios from univariate Cox regression analysis, the top 200 survival-related genes were evaluated for intersection with the top 200 recurrence-related genes, and 44 genes were obtained. Second, we examined the 44 genes that met the criteria of fold-change values between advanced stage and early stage samples of greater than 2 or less than 0.5. Ultimately, 17 genes were identified. A heat map of the 17 genes is depicted in the associated publication. Gene ontology and pathway enrichment analyses of the 17 genes were performed using Database for Annotation, Visualization and Integrated Discovery (DAVID). The major cellular component, biological process and molecular function of the 17 genes are associated with the extracellular region, intracellular signaling cascade, and protein binding and bridging, respectively. Two genes, COL11A1 and COL4A6, are involved in ECM-receptor interaction pathways. Notably, COL11A1 displayed the highest fold-change value in ovarian cancer disease progression; therefore, we selected COL11A1 for further experimental analysis.

2014-01-01 | E-GEOD-44104 | biostudies-arrayexpress

BIN2 Inhibition Suppress Cancer Progression and Protect Ovarian function through Downregulating HDAC1 and RPS6 Phosphorylation Respectively [CUT&Tag]

Project description:Malignant tumors, or cancers, are increasingly menacing people's life and health. For your female cancer patient, the ideal therapy should achieve dual purpose: suppress tumor progression meanwhile protect ovarian function. We previously showed that activated (phosphorylated) BIN2 in mouse ovaries regulates primordial follicle activation and oocyte quality through p-RPS6, and in this study, we found that BIN2 knockout or inhibition of BIN2 phosphorylation by BPP could suppress the genesis and progression of ovarian cancer. However, in human female ovarian cancer tissues, we didn’t see the increment of p-RPS6 although we observed a significant raise of p-BIN2. From this discrepancy between normal ovaries and ovarian cancer tissue, we guessed that p-BIN2 has other targets that are more important in ovarian cancer progression. Through mass spec identification, we found that only the constitutively active form of BIN2 (T423D & S424D) baits HDAC1, indicating that HDAC1 is a more important target of BIN2 in ovarian cancer. Next, we did saw Bin2 knockout or inhibition significantly decreased p-HDAC1 (S421) meanwhile increased H3K27ac. Moreover, chip seq showed that BIN2 inhibition significantly increased the binding of H3K27ac to multiple oncogenes. Besides, BIN2 knockout or inhibition could meanwhile protect ovarian function in mice with chemical carcinogen-induced in-situ ovarian cancers or with ovarian cancer cell transplantation. This study suggested that BIN2 inhibition could both suppress ovarian tumorigenesis and protect ovarian fertility, but through distinct mechanisms.

2024-07-01 | GSE244896 | GEO

ORAI1 channel function is a driver in oral cancer progression and pain

Project description:ORAI1 channel function is a driver in oral cancer progression and pain

| PRJNA992100 | ENA

BIN2 Inhibition Suppress Cancer Progression and Protect Ovarian function through Downregulating HDAC1 Phosphorylation

Project description:Malignant tumors, or cancers, are increasingly menacing people's life and health. For your female cancer patient, the ideal therapy should achieve dual purpose: suppress tumor progression meanwhile protect ovarian function. We previously showed that activated (phosphorylated) BIN2 in mouse ovaries regulates primordial follicle activation and oocyte quality through p-RPS6, and in this study, we found that BIN2 knockout or inhibition of BIN2 phosphorylation by BPP could suppress the genesis and progression of ovarian cancer. However, in human female ovarian cancer tissues, we didn’t see the increment of p-RPS6 although we observed a significant raise of p-BIN2. From this discrepancy between normal ovaries and ovarian cancer tissue, we guessed that p-BIN2 has other targets that are more important in ovarian cancer progression. Through mass spec identification, we found that only the constitutively active form of BIN2 (T423D & S424D) baits HDAC1, indicating that HDAC1 is a more important target of BIN2 in ovarian cancer. Next, we did saw Bin2 knockout or inhibition significantly decreased p-HDAC1 (S421) meanwhile increased H3K27ac. Moreover, chip seq showed that BIN2 inhibition significantly increased the binding of H3K27ac to multiple tumor suppressors. Besides, BIN2 knockout or inhibition could meanwhile protect ovarian function in mice with chemical carcinogen-induced in-situ ovarian cancers or with ovarian cancer cell transplantation. This study suggested that BIN2 inhibition could both suppress ovarian tumorigenesis and protect ovarian fertility, but through distinct mechanisms.

2023-10-20 | PXD046297 |

The role of ATAD2 in ovarian cancer growth and progression

Project description:The role of ATAD2 in ovarian cancer growth and progression

| PRJNA792585 | ENA

The role of DOT1L in ovarian cancer growth and progression

Project description:The role of DOT1L in ovarian cancer growth and progression

| PRJNA663771 | ENA